Alaska Medicaid Pharmacy and Therapeutics Committee Meeting January 19, 2018 Frontier Building, 3601 C Street; Room 890/896 <u>Agenda</u> Public Call in: 1.800.315.6338. Access code 24251#

8:00 am

8:05 am

- 1. Call to Order Chair
- 2. Roll Call

4.

3. **Public Comment**, including health care professionals

Class review, discussion & vote.

The Department's methods for class review are to better utilize the time of the P&T Committee. Classes shown in **Red*** and **Blue**** are classes where new information exists and industry testimony will be taken. Classes shown in **Green** are classes where no significant changes have been noted and no industry testimony will be taken. *New information includes: *new drugs or **new indications, new warnings, new head to head clinical evidence.*

AK Treatment		
Class	Drug Class	Status
Respiratory	COPD Agents	BLUE**
	Glucocorticoids, Inhaled, Single Entity	RED**
	Glucocorticoids, Inhaled, Combination	RED**
	Beta Agonists Bronchodilators, Long	GREEN
	Beta Agonists Bronchodilators, Short	GREEN
Allergy	Epinephrine, Self-Injected	RED**
	Intranasal Rhinitis Agents	RED**
	Leukotriene Modifiers	GREEN
	Antihistamines, Minimally-Sedating	GREEN
Immunological	Cytokine & CAM Antagonists, Non-GI Indications	RED**
	Immunosuppressants, Oral	GREEN
Dermatological	Antipsoriatics Topical	GREEN
	Immunomodulators, Atopic Dermatitis	GREEN
	Topical Steroids Low Potency	GREEN
	Topical Steroids Medium Potency	GREEN
	Topical Steroids High Potency	GREEN
	Topical Steroids Very High Potency	GREEN
	Acne, Topical	GREEN
Ophthalmics	Ophthalmic, Allergic Conjunctivitis	GREEN
	Ophthalmic, Antibiotics	GREEN
	Ophthalmic, Antibiotics-Steroid Combination	GREEN
	Ophthalmic, Anti-inflammatory	GREEN
	Ophthalmic, Glaucoma Agents	GREEN
	Ophthalmic, Immunomodulators	GREEN

7. Break as needed – 15 minutes

8. Review minutes from November 2017 meeting

9. Comments from Committee Members or Chair

10. Adjourn

Any pharmaceutical manufacturer may submit unsolicited material related to the agenda items by utilizing the Clinical Submission form. Clinical Submissions will be accepted until January 5, 2018 at 4:00pm AK local time. Forms may be found at: <u>http://dhss.alaska.gov/dhcs/Pages/pdl/download_pdl.aspx</u>.

Any member of the public, including health care professionals, may submit unsolicited material related to the agenda items by sending an email to <u>erin.narus@alaska.gov</u> or via mail to 4501 Business Park Blvd, Bldg L, Anchorage, AK 99503. Submissions should be received no later than January 17, 2018 to allow inclusion in the meeting.

Next Meeting Date: April 20, 2018